Glycolipid-Anchored Proteins on Bioengineered Extracellular Vesicles for Lipopolysaccharide Neutralization

Area of Science:

• Biotechnology
• Immunology
• Cell Biology

Background:

• Extracellular vesicles (EVs) are crucial for cell communication and can be engineered to display specific membrane proteins.
• Harnessing native EV membrane proteins for functional applications is a promising but underexplored area.
• CD14 is a key innate immune receptor for bacterial lipopolysaccharide (LPS).

Purpose of the Study:

• To bioengineer EVs displaying glycosylphosphatidylinositol (GPI)-anchored CD14.
• To investigate the functional implications of CD14-displaying EVs in response to LPS.
• To establish a platform for harnessing native GPI-anchored proteins on EVs.

Main Methods:

• Genetic engineering of producer cells to express GPI-anchored CD14.
• Enzyme cleavage assays to validate CD14 anchoring on EVs.
• Co-incubation of engineered EVs with mouse macrophages and LPS to assess cytokine response.

Main Results:

• Producer cells selectively displayed GPI-anchored CD14 over transmembrane proteins on EVs.
• Enzyme studies confirmed CD14 was GPI-anchored on the engineered EVs.
• EVs with CD14 significantly reduced LPS-induced cytokine responses in macrophages (50-90% reduction).

Conclusions:

• Bioengineered EVs can effectively display native GPI-anchored proteins like CD14.
• Harnessing native EV membrane proteins, particularly GPI-anchored ones, offers a viable strategy for functional applications, including toxin neutralization.
• The GPI-anchoring platform can be utilized to display diverse proteins on EV membranes for therapeutic or research purposes.